Therapeutics Alliances Team & Advisory Board | NYU Langone Health

Skip to Main Content
Therapeutics Alliances Therapeutics Alliances Team & Advisory Board

Therapeutics Alliances Team & Advisory Board

Faculty, staff, researchers, and advisors from NYU Langone and prominent biopharmaceutical companies and investment companies comprise the Therapeutics Alliances team and advisory board.

Nadim Shohdy, PhD, Director and Associate Dean

Nadim Shohdy, PhD

Dr. Shohdy co-founded Therapeutics Alliances in 2013 and directs the program to translate new NYU research discoveries into viable and de-risked drug discovery programs. Dr. Shohdy directs overall program operations and the development of new partnerships with industry, investors, and nonprofits, and coordinates business development and licensing efforts on the project pipeline of Therapeutics Alliances, working closely with NYU’s Industrial Liaison. Dr. Shohdy is also a research assistant professor in the Department of Cell Biology at NYU Langone.

Dr. Shohdy received his PhD with distinction in microbiology from Columbia University and was the 2006 Richard C. Parker Graduate Student Award recipient. His thesis work in Dr. Howard Shuman’s lab focused on elucidating virulence mechanisms of Legionella pneumophila. Dr. Shohdy completed his postdoctoral training at The Rockefeller University where he was awarded a National Institutes of Health (NIH) National Research Service Award Fellowship to study the cell biology of hepatitis C virus in Dr. Charles Rice’s lab. Dr. Shohdy then joined the International AIDS Vaccine Initiative (IAVI), a nonprofit product development partnership, as a research analyst in IAVI’s Innovation Fund. There he was involved in developing and managing collaborative alliances with biotechnology companies and academia. Dr. Shohdy then joined NYU’s Industrial Liaison where he was involved in licensing activities with biopharma and investors to launch new biotechnology startups.

Learn more about Dr. Shohdy.

Xinyan Huang, PhD, Assistant Director

Xinyan Huang, PhD

Dr. Huang is responsible for providing robust project management support and scientific oversight for all Therapeutics Alliances projects. She leverages her extensive expertise in drug discovery project leadership and more than eight years of experience in the pharmaceutical industry.

Before joining NYU, Dr. Huang worked as a senior research scientist in the Neuroinflammation Disease Biology Unit at Lundbeck, an international pharmaceutical company focused on discovering and developing novel therapeutics for central nervous system disorders. There she was a researcher and team/project leader for target identification and validation, assay development, high-throughput screening, hit identification, lead optimization, and candidate selection for clinical development.

Dr. Huang earned her PhD in biological science from the University of Toledo and completed her postdoctoral training at the University of Michigan where she focused on developing mouse models to study RGS proteins in cardiovascular and metabolic function. She has received a Multidisciplinary Cardiovascular Research Training Grant from the NIH, an Outstanding Postdoctoral Research Award from the Department of Pharmacology at the University of Michigan, and the Rising Star Award from the Healthcare Businesswomen’s Association.

Eric Ekland, PhD, Senior Research Analyst

Eric Ekland, PhD

Dr. Ekland is responsible for comprehensive scientific and business intelligence to help Therapeutics Alliances evaluate NYU research with potential for innovative drug discovery and guide the development of Therapeutics Alliances–supported work plans. Dr. Ekland leverages his experiences in early-stage biotechnology in the business and academic spheres to review the science, intellectual property, regulatory paths, and overall commercial potential for incoming projects.

Dr. Ekland received his PhD in biomedical sciences from the University of California, San Francisco, where he studied B-cell biology in the laboratory of Dr. Jason Cyster. He completed his postdoctoral training at Columbia University where he developed novel antimalarial therapeutics in the laboratory of Dr. David Fidock. He was the recipient of multiple awards including a Howard Hughes Medical Institute predoctoral fellowship and a Life Sciences Research Foundation postdoctoral fellowship. He has authored or coauthored more than 20 publications in leading journals including Science and Nature.

Before joining Therapeutics Alliances, Dr. Ekland worked as an associate research analyst at JMP Securities, a boutique investment bank with a significant focus on early-stage healthcare companies. In that capacity, Dr. Ekland holds both Series 7 and 63 licenses.

Brandon Hogstad, PhD, Business Development Manager

Brandon Hogstad, PhD

Dr. Hogstad is responsible for internally sourcing new and innovative drug discovery projects, experimental guidance for therapeutic target validation, work plan development and pipeline management, marketing to external commercial partners, and negotiation of licensing agreements. Dr. Hogstad leverages his scientific training and biotechnology commercialization experience to quickly assess the scientific validity, market opportunity, commercialization potential, and potential partners for Therapeutics Alliances technologies.

Dr. Hogstad received his PhD in biomedical sciences from the Icahn School of Medicine at Mount Sinai where he was awarded an NIH Ruth L. Kirschstein National Research Service Award to study mitogen-activated protein (MAP) kinase activation and novel therapeutics development for Langerhans cell histiocytosis in the laboratory of Dr. Miriam Merad.

Before his PhD, Dr. Hogstad worked as a researcher studying innate immune detection of HIV in the laboratory of Dan R. Littman, MD, PhD, at NYU Langone.

Beyond the lab, Dr. Hogstad has been an entrepreneurial fellow with Celdara Medical, where he vetted in-licensing opportunities for various biotechnologies. He also completed a business development internship with Mount Sinai Innovation Partners. Dr. Hogstad has more than a decade of experience in life sciences research, including basic biochemistry, pathophysiology and therapeutics development for orphan disease, HIV immunology, and development of combination targeted immunotherapies for cancers.

Internal Advisory Board

Dan R. Littman, MD, PhD
The Helen L. and Martin S. Kimmel Professor of Molecular Immunology, Department of Pathology
Professor, Department of Microbiology

Victor J. Torres, PhD
Associate Professor, Department of Microbiology

Kathryn J. Moore, PhD
The Jean and David Blechman Professor of Cardiology, Department of Medicine
Professor, Department of Cell Biology

Kwok-Kin Wong, MD, PhD
Director, Division of Hematology and Medical Oncology
The Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine

Adriana Heguy, PhD
Assistant Dean for Advanced Research Technologies
Professor, Department of Pathology

External Advisory Board

Brian Gallagher, PhD
Partner, Abingworth

David McElligott, PhD
Chief Scientific Officer, Petra Pharma Corporation

Jeanne Magram, PhD
Chief Scientific Officer, Quentis Therapeutics

Gerhard Mueller, PhD
Chief Scientific Officer, Gotham Therapeutics

Susan Froshauer, PhD
Vice President, CURE Collaborations

Stephen Squinto, PhD
Venture Partner, OrbiMed

Satish Jindal, PhD
Managing Director, BioMotiv

Martin Vogelbaum
Managing Partner, Inning One Ventures